54 results about "Oncovirus" patented technology

The invention relates to a method for preparing the suaveolic round leaf extractive which contains celery element or the chromocor compound with celery element as corn, or relative salt. The invention also provides relative quality control method, while said extractive can be used to prepare the drug for treating virus B hepatitis, thrombus, cancer, or the like.

The invention discloses a single-domain antibody combined with immune globulin, an anti-avian-influenza single-domain antibody, a bifunctional antibody and application thereof. The single-domain antibody capable of mediating and combining the immune globulin is screened from a constructed immune nano antibody gene library, the amino acid sequence of the single-domain antibody is shown as SEQ ID NO. 1-4, and the single-domain antibody can be specifically combined with human IgA, and the binding affinity with human IgG and mouse IgG is very low. The invention further provides the anti-avian-influenza single-domain antibody shown as SEQ ID NO. 5. The single-domain antibody is fused with other antibodies for tumors and viral pathogen antibodies or single-domain antibodies to construct a multifunctional specific fusion protein, and animal experiments prove that the constructed fusion protein has the effects of prolonging the half-life period of the functional antibody or the single-domain antibody in the body of an animal, effectively improving the bioavailability of the therapeutic antibody, remarkably enhancing the biological targeting treatment of the therapeutic antibody and the like.

A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen produced by or associated with a malignant cell or an infectious agent. Sub-human primate anti-idiotype antisera, especially from baboons, are preferred. Such anti-idiotype antibodies are used to make vaccines for inducing preventive immunity or a therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites.

This invention discloses immunopotentiating agents which stimulate an immune response. These agents are categorized into single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates. Heteroconjugate agents elicit or enhance a cellular or humoral immune response which may be specific for an epitope contained within an amino acid sequence. Enhanced hematopoieses by bone marrow stem cell recruitment was also a result of administering some of these agents. Examples of immunopotentiating agents include monoclonal antibodies and proteins derived from microorganisms (e.g., enterotoxins) which activate T cells. One method of treatment disclosed uses only the immunopotentiating agent to stimulate the immune system. Another uses adjuvants in combination with the agent. A third method employs heteroconjugates. Heteroconjugates comprise: (a) an immunopotentiating protein which is characterized as having an ability to stimulate T cells; and (b) a second protein having an amino acid sequence which includes an epitope against which a cellular or humoral response is desired. This invention also relates to a method of preparing the heteroconjugate, and to a method of stimulating the immune system in vivo in a novel way. One route of stimulation is to activate T cells, in some instances, specific subsets of T cells, by administering heteroconjugates containing an immunopotentiating protein and a second protein, to mammals. For this method of treatment, the second protein in the heteroconjugate is derived from abnormal or diseased tissue, or from an infectious agent; alternatively, the second protein is produced synthetically by standard methods of molecular biology. Sources of the second protein include tumors, viruses, bacteria, fungi, protozoal or metozoal parasites. Monoclonal antibodies or T cells prepared from mammals whose immune systems have responded to administration of the heteroconjugate may be produced and administered to induce passive immunity. A method of preparing a hybridoma which secretes said monoclonal antibodies and use of these monoclonal antibodies and T cells, are also disclosed. This invention is also directed to a vaccine comprising the heteroconjugate.

The invention discloses an application of baicalein to the preparation of a drug for preventing and / or treating nasopharyngeal carcinoma. The application firstly proves that baicalein can remarkably inhibit a viral protein EBNA1 on which an Epstein-Barr virus exists, and a cell can become a normal cell due to tumor virus loss caused by overlow existing quantity of the protein in the cell. Baicalein can be favorably used for treating precancerous lesion, the conversion of severe rhinitis to nasopharyngeal carcinoma is effectively stopped, and the application has important significance for treating the precancerous lesion of nasopharyngeal carcinoma and reducing the occurrence rate and fatality rate of nasopharyngeal carcinoma.

This invention relates to novel reagents and methods for the screening of compounds that may be agonistic or antagonistic to the binding of viral DNA to the chromosomes of host cells, that may be used in gene therapy and that may be used to treat tumor viruses.

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and / or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and / or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

The invention relates to the field of biological medicine, in particular to an anti-tumor or anti-virus vaccine with IL-9 as an adjuvant. The invention provides a medicine and / or vaccine for preventing and treating diseases, the medicine and / or vaccine comprises IL-9 and a specific antigen, and experimental results show that compared with other cytokines, IL-9 can significantly enhance the cell and humoral immune intensity induced by antigens such as viruses and tumors, promote immune memory formation and improve the antibody level in serum; compared with vaccines without IL-9, protein vaccines, DNA vaccines or RNA vaccines containing IL-9 can significantly improve the prevention and treatment effect on viruses or tumors, and have wide application prospects in prevention and treatment of diseases caused by tumors, viruses, pathogenic bacteria and the like.

The invention discloses a virus for inhibiting a Wnt signal and a method of inhibiting the Wnt signal by using the virus, and a method of treating a tumor by using the virus.

The invention provides construction of a nano-carrier for regulating body adaptive cell and humoral immunity and an application thereof. According to the nano-carrier disclosed by the invention, small molecules or polypeptides with endoplasmic reticulum tropism are modified on the surfaces of nano-particles loaded with antigens, and the total uptake amount, the transport path and the processing presentation mode of exogenous antigens in dendritic cells are changed, so that the cellular immunity and humoral immunity of the antigen specificity of a body are regulated and controlled. The nano-carrier disclosed by the invention can be a drug loading system such as cationic nano-emulsion, liposome or lipid nanoparticles, and the antigen can relate to tumor, virus or plasmodium specific antigen protein / polypeptide. The nano drug loading system mobilizes the anti-tumor, anti-virus or anti-parasitic infection specific immune response by improving the adaptive immunity of a body, especially the participation degree of cellular immunity, and has the characteristics of novel scheme, simple preparation and wide application range.

The invention provides a primer for detecting a goat endemic intranasal tumor virus and the application of the primer in an HRM (High Resolution Melting) detection reagent, and relates to the technical field of molecular biology. The primer provided by the invention is designed by comparison according to an ENTV-2 whole genome sequence and gene sequences of viruses such as ENTV-1, JSRV, ERVs and the like with high homology with the ENTV-2, the length of a corresponding PCR amplification target fragment is 108bp, the primer is applied to an HRM detection reagent, and by analyzing a dissolution curve of a PCR product and according to a specific dissolution peak and a TM value, the HRM detection reagent with high homology with the ENTV-2 can be used for detecting the ENTV-2 in the HRM detection reagent. According to the present invention, whether the amplification product is the target fragment is recognized, the specific probe and the sequencing are not required, the whole process is closed, the experiment accuracy is improved, the advantages of strong specificity, good repeatability, rapidness and low cost are provided, the method is suitable for the border inspection and quarantine of the sheep intranasal tumor, the blank of the research in the field at home and abroad is filled, and the important economic significance is provided.

A construction and use of an environmentally adaptive co-regulated mRNA nanodelivery system. By incorporating EACR molecules into mRNA nanoparticles, the microenvironment is remodeled to be suitable for robust and sustained mRNA expression, while tissue damage associated with the self-immunogenicity of mRNA drugs is avoided. The nanodelivery system is compatible with ionizable lipid nanoparticles, cationic liposomes, cationic nanoemulsions, and polymeric nanoparticles. The EACR molecules include: anti-inflammatory drugs, tyrosine kinases / adaptors, JAK / STAT and MAPK pathway inhibitors, nutrients and metabolites, membrane transporters / ion channels, phosphodiesterase and cellular stress inhibitors, and natural viral proteins. The therapeutic mRNAs may encode tumor, viral, or bacterial antigens, immunomodulatory factors, therapeutic antibodies, or functional proteins / enzymes, and can play a role in the fields of regenerative medicine, protein supplementation / replacement therapy, targeted gene editing, and immunotherapy.

The invention relates to an immune cell co-expressing an IL-21 and hrCD16 chimeric receptor, and the hrCD16 chimeric receptor comprises: (1) an extracellular recognition domain; (2) an extracellular spacer region; (3) a transmembrane area; (4) an intracellular signal transduction domain; optionally, the chimeric receptor further comprises (5) one or more co-stimulatory signaling domains; and / or (6) one or more cytokine receptor signaling domains. The invention also provides a combination comprising the immune cell and a tumor antigen targeting antibody or a viral antigen targeting antibody. The immune cell co-expression IL-21 provided by the invention not only can efficiently kill different types of tumor cells / virus infected cells, but also can act on para-line immune cells, and starts endogenous anti-tumor / virus immune response at the same time.

A recombinant oncolytic virus with improved safety and anticancer effect and a use thereof are disclosed. The recombinant oncolytic virus is obtained by inserting an HSV-TK fragment-encoding gene into a TK gene region to delete TK of Vaccinia virus. The oncolytic virus expresses an HSV-TK fragment to phosphorylate GCV so that cancer cells infected with the oncolytic virus and their neighboring cancer cells can be killed. GCV is also involved in the suppression of viral proliferation and thus can control side effects caused by a virus even upon the administration of a high dose of the virus.

Ironized viral particles such as ironized adeno-associated viral particles, which may carry a photosensitizer such as a KillerRed protein, and uses thereof in light-triggered virotherapy against tumor.

The present invention relates to Split-Intron Final Self-Inactivating (SIN) retroviral vectors which comprises a viral major splice donor (mSD) comprising mutations, a mouse mammary tumor vector long terminal repeat (MMTV-LTR) or a Type B leukemogenic virus long terminal repeat (TBLV-LTR), a eukaryotic splice acceptor (eSA), and a eukaryotic splice donor (eSD). Furthermore, the invention relation to the use and methods of uses of such vectors in gene therapy.

The present invention discloses an antibody-drug conjugate and a preparation method and application thereof, in particular, a conjugate of an anti-PD-L1 antibody and a TLR7 and / or TLR8 agonist and a pharmaceutical composition, preparation method and application thereof. The present invention obtains a modified anti-PD-L1 antibody with a mutant cysteine ​​by gene editing, which basically retains the structure of the original antibody and can be used for the construction of an antibody-drug conjugate. Through anti-tumor experiments, it was found that the obtained antibody-drug conjugate has better activity, such as strong anti-tumor activity, can significantly improve the survival rate of tumor-bearing animals, and has significantly reduced toxicity, less burden on the body of experimental animals, greatly reduces the minimum effective dose of small molecule drugs when used alone, expands its therapeutic window, and is expected to be used in the development of therapeutic drugs for various diseases (such as tumors, viral diseases such as hepatitis B, etc.), with good application prospects and value.

Disclosed herein are compositions that block entry of enveloped viruses into cells, polynucleotides encoding the same, pharmaceutical compositions, and methods of treating viral infections in subjects using the disclosed compositions. Also disclosed are compositions that make a cell susceptible to viral infection, polynucleotides encoding the same and methods of making a cell susceptible to viral infection, methods of targeting an oncolytic virus to a cell, and methods of inducing cell-cell fusion.

The present disclosure relates to recombinant oncolytic viral vectors for the treatment and prevention of cancers such as glioblastoma. The oncolytic viral vectors comprise one or more of the following features: miRNA target sequence(s) for viral replication restriction; transgene(s) encoding one or more payload molecules; a retargeting domain; mutation(s) in both UL30 and UL23 genes; and a protein with a syncytial mutation and a counterpart protein without the syncytial mutation.

The invention discloses an oligopeptide derivative based on lysosomal membrane protein 2A and application of the oligopeptide derivative. The oligopeptide derivatives disclosed by the invention are L2AK104, L2AK289, L2AK132 and L2ASIM1, and the amino acid sequences of the oligopeptide derivatives are shown as SEQ ID No.6 to SEQ ID No.9 in sequence. The oligopeptide derivative is composed of cell-penetrating peptides and oligopeptides, the oligopeptides are oligopeptides based on K104, K289, K132 and SIM1 sites modified by lysosomal membrane protein 2A polypeptide SUMO, and the amino acid sequences of the oligopeptides are sequentially shown as SEQ ID No.1-4; the cell-penetrating peptide is connected to the N terminal of the short peptide, and the amino acid sequence of the cell-penetrating peptide is shown as SEQ ID No.5. The four oligopeptide derivatives in the invention do not influence the cell activity and have no cytotoxicity, and the tumor virus KSHV is used as a research model, and in-vivo experiments repeatedly confirm that the four oligopeptide derivatives have a certain inhibition effect on the infection of viruses such as the KSHV and the proliferation of tumor cells. The compound can be used for preparing related drugs for resisting KSHV virus infection and treating tumor diseases, and has important application value in prevention and targeted treatment of virus related diseases such as KSHV.

Recombinant adenoviruses that selectively replicate in E2F deregulated tumor cells are described. The recombinant adenoviruses have a genome encoding a modified El A protein, a modified or deleted E4orf 1 protein, a modified or deleted E4orf6 / 7 protein, or any combination thereof, such that the recombinant adenoviruses exhibit replication defects in normal cells compared to tumor cells. In some instances, the recombinant adenovirus genomes encode additional modifications that target the recombinant adenoviruses to specific cell types, detarget the viruses from the liver, inhibit viral replication in the liver, and / or evade pre-existing neutralizing antibodies.

Methods for detecting viral integration events in a genome for a subject are described. The methods may comprise, for example, receiving, at one or more processors, sequence read data for a plurality of sequence reads obtained from a sample of the subject; aligning, at the one or more processors, each sequence read of the plurality of sequence reads with a human reference sequence and an oncovirus reference sequence to identify a subset of the plurality of sequence reads, each read in the subset comprising a first portion corresponding to the human reference sequence and a second portion corresponding to the oncovirus reference sequence; and determining, at the one or more processors, whether the identified subset of the plurality of sequence reads indicates occurrence of a viral integration event based on quantity information and location information of the subset of the plurality of sequence reads.

The invention discloses a double-antibody sandwich ELISA kit for detecting ENTV and JSRV and application of the double-antibody sandwich ELISA kit, and belongs to the technical field of biology. The double-antibody sandwich ELISA kit contains an ELISA plate coated with a monoclonal antibody for resisting goat endemic intranasal tumor virus p27 protein, a polyclonal antibody for resisting goat endemic intranasal tumor virus p27 protein and HRP (horse radish peroxidase) labeled goat anti-rabbit IgG (immunoglobulin G). Wherein the monoclonal antibody for resisting the goat endemic intranasal tumor virus p27 protein is secreted by a hybridoma cell strain ENTV-2C3, the hybridoma cell strain ENTV-2C3 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: C 2024412. The double-antibody sandwich ELISA kit established by the invention has the characteristics of high detection sensitivity and good specificity, can be used for detecting goat endemic intranasal tumor virus and sheep lung adenoma retrovirus, and provides a technical means for prevention and control of goat endemic intranasal tumor and sheep lung adenoma.

The invention discloses a human STING gene promoter inhibition regulatory region and application thereof. The human STING gene promoter inhibition regulatory region is shown in SEQ ID NO:1 in the description, and the 2033bp-2154bp is a main inhibition activity regulatory region of an STING gene promoter. As a drug target for the preparation of STING and other proteins, the human STING gene promoter inhibition regulatory region is capable of reducing expression levels of the human STING or other proteins by introducing the gene promoter inhibition regulatory region or promoting expression of the gene promoter inhibition regulatory region, then the gene promoter inhibition regulatory region can be applied to preparation of drugs for treating STING related diseases or other diseases; or, by cutting the human STING gene promoter inhibition regulatory region or through any treatment which can result failure of promoter activity inhibition, the transcriptional activity of STING can be improved, and thus the region can be applied to preparation of drugs for treating or preventing tumors and viral infectious diseases.

Methods for detecting viral integration events in a genome for a subject are described. The methods may comprise, for example, receiving, at one or more processors, sequence read data for a plurality of sequence reads obtained from a sample of the subject; aligning, at the one or more processors, each sequence read of the plurality of sequence reads with a human reference sequence and an oncovirus reference sequence to identify a subset of the plurality of sequence reads, each read in the subset comprising a first portion corresponding to the human reference sequence and a second portion corresponding to the oncovirus reference sequence; and determining, at the one or more processors, whether the identified subset of the plurality of sequence reads indicates occurrence of a viral integration event based on quantity information and location information of the subset of the plurality of sequence reads.

The invention discloses an engineered immune killer cell as well as a preparation method and application thereof. The engineered immune killer cell is an immune killer lymphocyte induced by reprogramming a human T cell, retains a marker and a function of the human T cell derived from the engineered immune killer lymphocyte, and has a marker and a function of an NK cell; cAR molecules for recognizing tumor and virus related antigens or cells for specifically recognizing tumor TCR molecules are transfected and expressed in the obtained immune killer lymphocytes. The engineered immune killer cell not only has a wider-spectrum tumor antigen recognition and killing function and a function of recognizing and removing microorganisms such as viruses and bacteria, but also has an efficient in-vitro amplification capability and an enhanced tumor specific recognition and killing function.

In one aspect, composition generally includes a virotherapeutic agent and an inhibitor of tumor necrosis factor (TNF). In one or more embodiments, the virotherapeutic agent can include an oncolytic virus. In one or more embodiments, the inhibitor of TNF comprises can include an antibody, or a fragment thereof, that binds to TNF. In another aspect, a method of treating a tumor in a subject generally includes co-administering to the subject an oncolytic virotherapeutic agent and an inhibitor of tumor necrosis factor (TNF). In one or more embodiments, the oncolytic virotherapeutic agent is administered intratumorally. In one or more embodiments, the inhibitor of TNF is administered systemically.